China is facing a demographic bomb— and it could handcuff Beijing’s ambitions

Last week, Beijing’s release of China’s national birth count for 2025 left demographers stunned. The national birth total ...

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s …

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...